<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229927</url>
  </required_header>
  <id_info>
    <org_study_id>HT-007-04</org_study_id>
    <nct_id>NCT04229927</nct_id>
  </id_info>
  <brief_title>BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of BPDO-1603 in Patients With Moderate-to-severe Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyundai Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hyundai Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, active-controlled, phase III clinical trial to
      evaluate the efficacy and safety of BPDO-1603 in patients with moderate-to-severe Alzheimer's
      disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SIB total scores</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CIBIC-plus total score</measure>
    <time_frame>at Week 24 (Baseline score will be from CIBIS</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">712</enrollment>
  <condition>Moderate-to-severe Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPDO-1603</intervention_name>
    <description>Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug
Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A voluntary, written informed consent from the patient or the patient´s
             representative.

          -  Male or female patients ≥ 45 years of age as of the date of informed consent.

          -  Diagnosed with probable AD according to the National Institute on Aging-Alzheimer's
             Association [NIA-AA (2011)] criteria.

          -  MMSE score of ≥ 5 and ≤ 20 during screening period.

          -  CDR-GS of 2 ~ 3 or GDS of 4 ~ 7 during screening period.

          -  Ongoing cholinesterase inhibitor therapy with stable dose of 10 mg/day donepezil
             hydrochloride for more than 12 weeks (inclusive) prior to screening, and can continue
             this therapy until randomization without any change in the dosage regimen of donepezil
             hydrochloride.

        Exclusion Criteria:

          -  Magnetic resonance imaging (MRI) or computed tomography (CT) findings obtained within
             the past 12 months (ie, 48 weeks) from screening or at screening, as a cause of
             dementia other than probable AD.

          -  History of other organic disease, such as vascular dementia, CNS infections (e.g.,
             human immunodeficiency virus [HIV], syphilis), head injury, Creutzfeldt-Jakob disease,
             Niemann-Pick's disease, Huntington's disease, Parkinson's disease, epilepsy, or
             stroke.

          -  Evidence of other neurological disorders which include seizure disorder that may
             interfere with the patient's cognition or ability to perform the study procedures.

          -  Use of Memantine Hydrochloride within 1 month prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seonghye CHOI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nara LEE</last_name>
    <phone>82-2-2600-3869</phone>
    <email>nara.lee@hdpharm.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sumin SON</last_name>
    <phone>82-2-2600-3817</phone>
    <email>smson@myhdpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seonghye CHOI</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

